Zomig is the brand name for the migraine medication zolmitriptan. It belongs to a class of drugs known as selective serotonin receptor agonists. The medication is used acutely to treat migraine attacks with or without aura in adults. Zomig works by binding to serotonin 5-ht1b and 5-ht1d receptors in the brain. This binding leads to vasoconstriction of cranial blood vessels and modulation of pain pathways. The resulting vasoconstriction reduces the pulsatile expansion of dilated arteries that is thought to underlie migraine pain. By dampening trigeminal nerve activation the drug provides relief from headache and associated symptoms.

Zomig is a brand name for the migraine medication zolmitriptan. It is classified as a serotonin 5-ht1b/1d receptor agonist. By binding to these receptors it reduces the release of inflammatory neuropeptides in the trigeminal nerve pathways. This action constricts dilated blood vessels and blocks pain transmission in the brain. The resulting decrease in vascular inflammation and neuronal signaling alleviates the throbbing headache associated with migraines. Zolmitriptan's mechanism therefore targets the underlying neurovascular processes that trigger migraine attacks.

Zomig may cause mild nausea in some patients. Headache is reported as a frequent complaint. Dizziness or lightheadedness can occur during treatment. Some users experience dry mouth or altered taste sensation. Fatigue or mild drowsiness is occasionally noted. Warm or tingling sensations in the face or extremities have been observed. These effects are generally transient and resolve without intervention.

Some users experience headache after taking Zomig. Others may notice a feeling of dizziness or lightheadedness. Nausea can occur shortly after dosing. Fatigue or tiredness is reported by some individuals. Muscle pain or joint discomfort may be felt. Tingling or numbness in the extremities has been noted. Dry mouth or mild throat irritation can happen. Some people report a temporary change in taste perception.